Background and Aims: Sedation directed by anesthesia professionals (ADS) for GI endoscopy is used
Introduction
Sedation is an integral part of the majority of GI endoscopic procedures performed in the United States.
The goals of sedation are to improve the patient experience by reducing pain and anxiety, ultimately leading to better adherence to recommended screenings and follow-up 1 . Options for sedation are primarily endoscopists targeting minimal to moderate sedation (endoscopist directed sedation -EDS) or anesthesia professionals that typically target deep sedation or general anesthesia (anesthesia-directed sedation [ADS] ). Anesthesia professionals have become increasingly involved in sedation for screening colonoscopies, rising from 11% in 2001 to 53.4% in 2015 2, 3 . This increase is likely due to a perceived increase in satisfaction and throughput with propofol sedation compared with a narcotic/benzodiazepine based sedation 4 . This practice is increasing overall procedural costs by approximately 20% 2 .
The Centers for Medicare and Medicaid Services (CMS) recently released a ruling that will ensure coverage of anesthesia services for screening colonoscopies instead of placing the burden upon the patient 5 . The costs for involving anesthesia professionals are substantial 3 . An important inquiry therefore is what benefit is brought to the patient by using anesthesia professionals in regards to patient safety and the quality of the procedure 2, 6 . The aim of better health care at a reduced cost has become a driving initiative that forces the health care system to ask this question 7 .
Background
With regard to colonoscopy, there have been several studies addressing the method of sedation used and the effect on adenoma detection rates, a measure of quality of the procedure. One study showed there was no difference in the detection of polyps using moderate or deep sedation 8 . Similarly, other studies comparing propofol delivered by an anesthesiologist and endoscopist-directed M A N U S C R I P T
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midazolam/fentanyl based sedation, found no differences in the number of patients who had adenomatous polyps detected 9, 10 .
Without a clear benefit in the quality of the colonoscopic examination, the increased cost for the use of ADS could potentially be justified by improved safety. As an appropriately powered randomized prospective controlled trial would be impractical due to the rarity of significant events, a few investigators have conducted retrospective studies. An increased rate of perforations during colonoscopies under propofol sedation and an increased risk of aspiration pneumonia with sedation delivered by anesthesia professionals have been observed [11] [12] [13] . With this landscape in mind, we 
Methods
The data for this study came from the National Endoscopic Database (NED), a database of gastrointestinal endoscopy procedure reports. The database is created and maintained by CORI, a large multicenter consortium of gastroenterology practices. From 2002-2013, 84 practice sites, including university medical centers, Veteran Affairs Health Care Systems and gastrointestinal private practices, contributed procedure reports to the database. Demographics, provider, and procedure data were collected in patients 18 years of age and older for all EGDs and colonoscopies over this time period.
Participating sites agree to use a structured computerized report generator to produce all endoscopic reports and comply with quality-control requirements. Each site's data files are transmitted electronically to a central data repository, the NED. The data that are transmitted from the local site to the NED do not contain most patient identifiers and qualifies as a Limited Data Set under 45 C.F.R.
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Section 164.514(e). The NED is reviewed by the institutional review board of the Oregon Health & Science University (eIRB no. 7331), and most recently approved in September 2014. This study used a limited dataset and was therefore exempted from further institutional review board review.
Primary Outcome Variable
The primary outcome variable was defined as a serious adverse event (SAE) requiring intervention. This was defined as any event requiring administration of cardiopulmonary resuscitation (CPR), hospital or ER admission, administration of rescue / reversal medication, emergency surgery, procedure termination due to an adverse event, intra-procedural adverse events requiring intervention, or blood transfusion.
Independent Variable of Interest
The independent variable of interest was the specialty of health care provider who was directly responsible for the administration of procedural sedation, as documented in the CORI procedure report.
This was defined as an anesthesia professional (anesthesia-directed sedation [ADS]) (anesthesiologist or nurse anesthetist) or a non-anesthesia professional (endoscopist-directed sedation [EDS]), specifically the endoscopist or other non-anesthesiologist procedure staff. Those sedation providers with ambiguous status (eg, "physician," "resident," and "technician") were considered to be unknown, and were excluded from the analysis.
Statistical analysis
Data were analyzed using both multivariate logistic regression modeling and propensity score analyses.
Analyses involving propensity scores included adjusting for propensity. All analyses were performed using SAS version 9.4 software (SAS Institute, Cary, NC). 
Propensity score analyses
Because this is a retrospective review of observational data, there is a risk of inherent bias on selection of whether an anesthesia professional (ADS) or endoscopist (EDS) provides sedation. To help manage this bias, propensity scores were calculated. A propensity score is the probability of a treatment being assigned to a patient, based on observed characteristics (collected covariates). For this analysis, that treatment was if an ADS was used. When using a propensity score, it is possible to mimic some, but
clearly not all, of the benefits when doing a randomized controlled trial 14 . This score can be used to adjust for the likelihood of being in the ADS (treatment) or EDS (non-treatment) groups, helping to ensure that both groups are comparable for all observed variables 15 .
For each colonoscopy and EGD in the cohort, a propensity score was calculated. In this study, we calculated propensity scores measuring the likelihood that a given procedure would use ADS versus EDS, regardless of the actual sedation provider status. A score was calculated using separate multivariate logistic regression models, for colonoscopy and EGD. The output from each procedure was assessed as a likelihood from 0% to 100% for having used ADS, and this value was used in the logistic regression 
Results

Patient demographics
The demographics of the 1,388,235 procedures evaluated are shown in Table 1 . There were 880,182
colonoscopies and 508,053 EGDs. Mean patient age was 60.1 (12.5) years for colonoscopy and 58.4
(15.9) years for EGD. Most patients were ASA physical classification I/II (84% colonoscopy, 74% EGD), outpatients, and received their procedures at a community, HMO, or private practice. 182,694 (21%) of the colonoscopy procedures and 115,320 (23%) of the EGD procedures used ADS respectively. Among EDS procedures, the prevalence of propofol use was low at 2.9% for colonoscopies and 2.5% EGDs.
Significant adverse events
As stated above, an SAE was defined as any event requiring administration of cardiopulmonary resuscitation (CPR), hospital or ER admission, administration of rescue / reversal medication, emergency surgery, procedure termination due to an adverse event, intra-procedural adverse events requiring intervention, or blood transfusion. Table 2 shows a descriptive breakdown of the SAE events. Overall, for colonoscopy, EDS had a numerically higher SAE rate (0.28%) compared with ADS (0.20%). This increase is primarily due to an increased use of rescue medications and reversal agents, where ADS used only 0.07% compared with 0.16% compared with EDS. For EGD, ADS had a numerically higher SAE rate (0.39%) compared with EDS (0.32%). As with colonoscopy, there was a similar rate of rescue medications M A N U S C R I P T
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/ reversal agents used in both groups with EDS having an increased use (ADS 0.07%, EDS 0.16%). Unlike colonoscopy, for EGD there was a significant increase in airway management related SAEs for ADS (0.14%) compared with EDS (0.02%).
The SAE risk stratified by procedure indication is shown in Table 3 . Although procedure indication was taken into account in the multivariate logistic regression analysis, the raw SAE rates were still assessed to determine what influence it may have on the rates. For colonoscopy patients indicated with a positive FOBT (0.39%) or hematochezia / melena / anemia (0.33%) the SAE rate was higher compared with the other procedure indications (0.22% -0.26%). For EGD patients indicated with a therapeutic intervention (0.95%), bleeding / varices / anemia (0.59%) had a higher SAE rate compared with the other indications (0.13%-0.39%).
Risk Factors for SAEs: Multivariate Logistic Regression Analysis
The results of the multivariate logistic regression analysis are shown in 
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A trainee being present also increased the risk of SAEs for EGD procedures. Table 5 provides the SAEs for EGD and colonoscopy stratified by the presence of a trainee, the sedation provider and the site type.
Consistent with the increased risk of SAEs, for EGD procedures the presence of a trainee was associated with a higher rate of SAEs at all three site types and both sedation providers. SAEs were more prevalent with ADS in both the Trainee Present and Trainee Not Present groups. The most significant difference was seen at the community / HMO sites (EDS: trainee present 0.92%, trainee not present 0.22% and ADS: trainee present 1.08%, not present 0.29%). For colonoscopy, there were no differences seen across all three site types and both sedation provider, except for the VA/military sites with ADS which had the highest observed rate (trainee present 1.27%, trainee not present 0.38%).
Sedation Provider and Risk of SAE: Regression Analysis Adjusted for Propensity Score
In multivariate logistic regression analysis, the use of ADS was associated an increased risk for SAEs when compared with EDS for EGD (OR, 1.34; 95% CI, 1.13, -1.58), as shown in Table 4 . There was no statistical difference for colonoscopy, with an OR of 1.18 (95% CI, 0.99 -1.39] for colonoscopy. To better assess this result of whether ADS is associated with an increased SAE risk, a propensity-adjusted risk assessment for SAEs was performed, with the results shown in Table 6 . For colonoscopy, after adjusting for the likelihood (propensity) of using ADS, the risk of a SAE was still not significantly different between ADS and EDS, with an OR of 0.93 (95% CI, 0.82 -1.06). For EGD, after adjusting for the likelihood (propensity) of seeing an anesthesia professional, the risk of SAEs was greater when sedation was provided by an anesthesia professional, with an OR of 1.33 (95% CI, 1.18 -1.50).
Sedation Provider and Risk of SAE: Stratified by ASA Classification
To further evaluate the association between ADS and the risk of SAEs for EGD, multivariate logistic regression analysis was used on data stratified by ASA I/II and ASA III to see if there is difference in SAE M A N U S C R I P T
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risk for these two populations. The results are shown in 
Mortality
The mortality results are shown in Table 7 . 
Discussion
There has been a substantial increase in the utilization of anesthesia professionals providing sedation for routine endoscopic procedures, with rates regionally exceeding 50% [2] [3] [4] . This results in increased costs of endoscopic procedures, at a time when the cost of health care is putting a severe strain on the system.
Additionally in certain areas of the United States there is a shortage of anesthesia providers so special consideration must be taken to ensure the proper allocation of limited health care resources 16 . In light M A N U S C R I P T
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of CMS's decision on paying for anesthesia services for all screening colonoscopies, the potential safety and quality benefits need to be critically defined, especially given that the majority of the increase in anesthesia services has been seen in low-risk patients 5, 16, 17 .
This study of 1.38 million procedures from 84 practice sites, including university medical centers, Veteran Affairs Health Care Systems and gastroenterology private practices, addresses the safety aspect of that question. The sample size of 1.38 million procedures using propensity score analysis allows for a large number of covariates to be accounted for, providing greater confidence in the results. A prospective study of sufficient size will not be conducted given the logistical complexity and costs.
Therefore, CORI-NED's large database allows a robust analysis of safety outcomes as a function of the sedation provider. We found that the propensity adjusted SAE risk for pooled ASA physical classification patients undergoing ADS was similar to EDS for colonoscopy but higher for EGD procedures.
Additionally, with further stratification into ASA class I/II and III, the use of ADS was associated with higher odds for an SAE for ASA I/II/III subjects undergoing upper endoscopy. When dichotomized into ASA I/II and ASA III for patients undergoing colonoscopy, the SAE risk for ADS and EDS were similar.
Several other risk factors were significantly associated with an increased risk of SAE beyond ASA and the sedation provider. These included patient age, the presence of a trainee and Academic or Military/VA site type. Certain indications for colonoscopy or EGD had higher raw rates as well. It is not surprising that patient factors (age, comorbidity), procedures with a higher likelihood of therapeutic interventions or the presence of less trained endoscopists would be associated with SAEs. There is a possibility that there is a synergy between risk factors that played a role, as table 5 suggests. However, controlling for these factors in multivariate logistic and propensity adjusted analyses did not eliminate the significant association between ADS and SAEs in EGD procedures.
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The fact that the raw SAE rate for colonoscopy of 0.20% for ADS compared with 0.28% for EDS failed to reach significance whereas for EGD 0.39% for ADS compared with 0.32% for EDS did reach statistical significance warrants some discussion. It is important to note that these are raw incidence rates and do not account for confounding variables. When age, gender, ASA classification, narcotic use, sedative status, trainee present, site type and indication are taken into account, no significant association is found between sedation provider and colonoscopy. Therefore, although EDS does have a higher rate when not including confounding factors, once confounding factors are taken into account there is no longer an increase seen in the SAE rate for colonoscopy. A trend seen in the EDS group for colonoscopy and EGD alike was an increase in the use of rescue and reversal medications compared with ADS. This may in part be due to the fact that EDS is done with traditional benzodiazepine/narcotic based sedation where a reversal medication is available, compared with ADS which predominantly uses propofol based sedation, where a reversal agent is not available. Of note, for EGD procedures, ADS had significantly more airway management SAEs.
A potential weakness of this study is the retrospective design. The data collected in the NED database does not contain all potential demographic and procedural data, such as body mass index and Mallampati score. One of the key procedural data points missing from the database is the type of sedation given by the provider (the targeted level of sedation and if the patient was intubated or not). In addition to demographic and procedural data, we also cannot be assured that all events identified in this study as an SAE were captured, especially less significant events such as the use of a nasal or oral airway.
The propensity score analysis, although superior to a simple regression analysis, still will have some hidden biases in the match results, factors that were not observed that can influence the scores.
Although it mimics some of the benefits of a randomized controlled trial, it should not be confused as
being equivalent to a randomized controlled trial. It must be emphasized that to our knowledge, this is the first time that this methodology has been applied to the question of endoscopic sedation and SAEs, representing a robust attempt to remove bias in addition to the traditional multivariate analysis with adjustment.
As previously mentioned, there has been no study published showing a quality benefit based on the method of sedation (polyp detection or adenoma detection rate) 8, 9, 18, 19 . A benefit has been seen with anesthesia professionals using propofol is patient satisfaction. In a meta-analysis of 36 moderate sedation studies, propofol sedation provided slightly more patient satisfaction when compared with midazolam plus narcotics 20 . It is unclear if the increase in patient satisfaction is due to the presence of an anesthesia professional or the use of propofol.
For safety, a smaller retrospective study of 118,004 colonoscopies, compared propofol and non-propofol administration (fentanyl, midazolam, meperidine, and/or diazepam), showing a 2.5 increased rate in colonoscopic perforations for therapeutic colonoscopies (6.9 vs 2.7 per 10,000; p=0.0015) in the propofol administration group (administered by anesthesia professionals) 11, 13 . Another study of 165,527 colonoscopies in 100,359 patients found an increased risk of aspiration pneumonia when sedation was delivered by an anesthesia professional 12 .
Most recently, a claims data analysis of more than 3 million colonoscopies found a 13% increase in 30-day adverse events when anesthesia was used 21 . Though an increased risk of an SAE with colonoscopy was not seen in this study, it cannot be excluded that there is an association for SAEs that might present or be diagnosed in a delayed fashion.
This study addresses the question of safety with a comprehensive view of patient risk, assessed by the SAE rate, a significantly greater size compared with most other retrospective studies, particularly those M A N U S C R I P T
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using endoscopic reports or patient medical records. It accounts for many covariates both in the logistic regression analysis and the propensity score analysis. The majority of the data was ASA I/II/III patients.
In reviewing the data, pooled and stratified by ASA classification I/II and III, it appears there is no clinical safety benefit with ADS. In fact, in the case of EGD, ADS is associated with an increased risk of SAEs for ASA I, II, and III patients. It is clear from the data and the confines of our SAE definition set that anesthesia professional utilization does not reduce the risk of an SAE when compared with endoscopist directed sedation.
It is unclear why there was no benefit in using an anesthesia professional in reducing the SAE incidence, including ASA III patients, who are more likely to experience an SAE. There are several potential reasons that ADS sedation may not bring a benefit. The most likely possibility is the level of sedation. Anesthesia professionals are trained to provide deep sedation and general anesthesia, levels of sedation that have increased risks of an SAE. Additionally, the level of sedation may not be aligned with the procedure, resulting in extended periods of over-sedation, especially during reduced stimulus. EGD patients, where an increase in SAE risk was seen, deeper levels of sedation likely blunted protective reflexes, perhaps contributing to the increase in the risk for cardiopulmonary unplanned events. The collected data does not allow us to determine if the increased risk for EGD is due to aspiration or respiratory depression.
Future studies would be useful to understand the reason and provide clinical insight on how to reduce this risk. There are other reasons that could account for this, including drug selection (eg. propofol), poly-pharmacy, and other un-measured patient and procedure variability.
Given the small sample size of ASA IV/V patients in the database, no conclusions can be drawn for these patients from this analysis, especially given the fact that very few did not use an anesthesia professional.
The database appears to reflect actual colonoscopy / EGD procedures where the majority of procedures 
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